Foundation for Angelman Syndrome Therapeutics
The Foundation for Angelman Syndrome Therapeutics (FAST) is an Austin, Texas–based public charity formed in 2008. It supports research and other work intended to advance treatments and a cure for Angelman syndrome, alongside education, advocacy, and community support.
Foundation for Angelman Syndrome Therapeutics at a glance
In short: Foundation for Angelman Syndrome Therapeutics gave $7.9M across 10 grants in 2024 (avg $792K), mostly in Pennsylvania. Source: 2024 IRS Form 990.
- Annual giving (2024)
- $7,921,275
- +42.2% vs 2023
- Grants made (2024)
- 10
- -41.2% vs 2023
- Average grant
- $792,128
- +141.7% vs 2023
- Median grant
- $242,378
- Total assets
- $44,915,881
- -23.1% vs 2023
- Primary geography
- Pennsylvania (74% of itemized 2024 grant dollars)
- Latest 990 filing
- Form 990, 2024 View filing
Data from IRS Form 990, 2024; updated October 2026.
How to apply to Foundation for Angelman Syndrome Therapeutics
- How to Apply
-
FAST uses a rolling application process; applicants should submit a letter of intent for the relevant program before applying. General eligibility is typically limited to nonprofit institutions, with rare exceptions for contract research organizations or industry scientific teams; individual applicants should have training and experience at least equivalent to the PhD or MD level.
- Review Cycle
- Applications are considered on a rolling basis, with no fixed deadline stated.
- Deadline
- Applications are considered on a rolling basis, with no fixed deadline stated.
- Contact
Mailing address: 5900 Balcones Drive 8754, Austin, TX 78731
Phone: (866) 783-0078
Application details from Grantable's research on the foundation's public materials; confirm on its website before applying.
Open Grants
5 open opportunities from Foundation for Angelman Syndrome Therapeutics
FAST IMPACT Award (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials)
Foundation for Angelman Syndrome Therapeutics
Amount
Up to $1,000,000 per year
Deadline
Rolling
FAST Innovation Seed Grant
Foundation for Angelman Syndrome Therapeutics
Amount
$10,000 - $50,000
Deadline
Rolling
FAST Postdoctoral Fellowship
Foundation for Angelman Syndrome Therapeutics
Amount
Up to $50,000 per year for up to two years
Deadline
Rolling
Who Foundation for Angelman Syndrome Therapeutics funds
How this funder distributes its grants
Top Recipients
Top 9 recipients in 2024
The largest 2024 recipient was University of Pennsylvania ($5.9M). Together the top 9 received $7.9M.
Grant Size Distribution
43 grants across all recorded years
The most common grant size was in the $100–250K range: 13 grants of 43 (30%).
Geographic Focus
Where this funder awards grants
FAST’s 2024 grants went to recipients in Pennsylvania, California, Massachusetts, Illinois, North Carolina, Rhode Island, and Washington, DC. Pennsylvania accounted for 74% of grant dollars, followed by California at 8%, Massachusetts at 6%, Illinois at 4%, and North Carolina at 4%. FAST’s Innovation Seed Grant and New Investigator Award are described as having international geographic scope.
Grant Distribution by State
Share of 2024 grant dollars across all 10 itemized grants.
States
Cities
How Foundation for Angelman Syndrome Therapeutics gives
- Giving grew 172% from 2021 to 2024. Method
From the foundation's IRS Form 990 filings. Methodology.
Giving History
Giving Over Time
Total grant dollars and number of grants per year
From 2020 to 2024, annual grant giving ranged from $800K (2022) to $7.9M (2024). In 2024 it made 10 grants totaling $7.9M.
Grants by year
Grant recipients and amounts by year
| Recipient | Purpose | Amount |
|---|---|---|
| University of Pennsylvania Philadelphia, PA | Upenn 2023: Research, Collaboration & License Agreement | $5,860,869 |
| Boston Children's Hospital Boston, MA | FT2022-006: Abom - Natural History Study | $470,957 |
| Rush University Medical Center Chicago, IL | Rush Coe | $320,500 |
| Duke University Charlotte, NC | FT2018-005 Amended: Gpic-Comm | $317,848 |
| Regents of the University of California Davis Davis, CA | Ft2022-007: gastrointestinal biomarkers in preclinical models of angelman syndrome | $274,044 |
| The Regents of the University of California San Francisco San Francisco, CA | Ft2023-002: developing a crispra therapy for the classi/ii deletion genotype of angelman syndrome | $210,711 |
| Brown University Providence, RI | Ft2022-005: development of bdnf potentiating therapeutics for motor and cognitive dysfunction in as | $150,000 |
| Children's Research Institute Washington, DC | Ft2022-003: peak alpha frequency as an eeg biomarker for angelman syndrome | $140,846 |
| Keck Graduate Institute of Applied Life Sciences Claremont, CA | Ft2022-002: targeting angelman syndrome therapeutics to the brain utilizing novel cell penetrating peptides | $125,000 |
| Brown University Providence, RI | PD2023-001: Postdoctoral Fellowship Program | $50,500 |
Ready to take the next step with Foundation for Angelman Syndrome Therapeutics?
Financial History
Multi-year comparison from IRS filings
| Filing year | Total Assets | Revenue | Expenses | Grants paid | Grants | Net Investment Income |
|---|---|---|---|---|---|---|
| 2024 | $44,915,881 | $5,388,260 | $10,391,969 | $7,921,275 | 10 | $1,677,094 |
| 2023 | $58,430,242 | $6,525,815 | $23,229,158 | $5,572,273 | 17 | $2,734,710 |
| 2022 | $63,075,354 | $52,477,819 | $8,933,021 | $800,071 | 4 | $47,780,150 |
| 2021 | $17,749,994 | $3,977,487 | $5,835,365 | $2,916,405 | 7 | $-181,056 |
| 2020 | $18,338,531 | $9,357,654 | $3,052,395 | $2,368,927 | 5 | $-436,697 |
Research compiled by Grantable AI from public sources. Last updated October 2026.
Mission & Focus Areas
In its filing, FAST describes itself as an organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through research funding, education, advocacy, and community support. Its stated primary goal is to advance research toward a cure by providing grants to universities for research and testing.
FAST’s website identifies treatment development as a central research focus, including gene modification, disease modification, symptom-alleviating therapeutics, drug-screening tools, biomarkers, outcome measures, and preparation for clinical trials. Its programs include FAST-TRAC awards for translational research, New Investigator Awards for early-career academic researchers pursuing translational research, IMPACT awards for comprehensive translational projects toward IND-enabling work, and Innovation Seed Grants for proof-of-concept research.
FAST generally funds nonprofit institutions. Its application information also says that, in rare circumstances, it funds contract research organizations or industry scientific teams. The grantees’ own stated missions illustrate the range of organizations supported: the University of Pennsylvania describes a public-service mission that includes research and patient care; Rush University Medical Center says its mission integrates patient care, education, research, and community partnerships; Children’s Research Institute describes translational and clinical research and education focused on childhood diseases; and Keck Graduate Institute describes a mission centered on education and translational research in healthcare and the life sciences.
Grantmaking
In filing year 2024, FAST reported 10 grants totaling $7,921,275. The grants ranged from $50,500 to $5,860,869, with a median of $242,378. The largest award was $5,860,869 to the University of Pennsylvania for a research, collaboration, and license agreement. Other notable awards included $470,957 to Boston Children’s Hospital for a natural history study; $320,500 to Rush University Medical Center; $317,848 to Duke University; and $274,044 to the University of California, Davis, for research on gastrointestinal biomarkers in preclinical Angelman syndrome models.
FAST’s website describes a rolling application process. For FAST-TRAC and IMPACT applications, applicants must first submit a letter of intent (LOI) to assess whether a proposed request is feasible. The LOI calls for a project description with objectives and rationale, a proposed budget and duration, preliminary data, and a CV or biosketch; the website specifies that the LOI, excluding the CV, should be no more than three pages. New Investigator Awards are for applicants within their first five years of an academic position and support translational research. FAST-TRAC awards are generally one or two years, with a maximum recommended amount of $150,000 per year. IMPACT awards may provide up to $1 million per year. The Innovation Seed Grant offers one-time awards of $10,000 to $50,000 for proof-of-concept research.
FAST says proposals receive scientific peer review by members of its Scientific Advisory Board or outside subject-matter experts. Applicants must avoid submitting essentially the same research focus from the same organization, and must notify the SAB chair if overlapping work receives another grant during review. Human-subjects projects require IRB approval before funds are disbursed; animal research requires IACUC approval before work begins. FAST does not pay indirect costs for its Grant-In-Aid or Postdoctoral Fellowship programs and may pay up to 5% for FAST-TRAC, IMPACT, Investigator Grants, and other investigator-proposed clinical development programs.
Leadership & Key People
Leadership team and compensation from IRS filings
The 2024 filing lists Ryan Jacob as chairperson; Michael Hanrahan as vice chairperson and treasurer; Guy Shapiral as treasurer; Amelia Beatty as secretary; and Karly Warner, John Schlueter, Kelly David, Ben O’Connor, Roy Azout, and Lauren Hoffer as directors. The filing lists Michael Hanrahan as “VICE CHAIRPERSON AND TR” and Guy Shapiral as “TRESURER.”
Foundation for Angelman Syndrome Therapeutics is led by Alana Newhouse, President & CEO on every filing since 2022; 4 of 16 officers listed in 2024 are compensated.
Officers on the 2024 filing
Alana Newhouse
President & CEO
On filings since 2022
40 hrs/week
$50K (2022) → $245K (2024)
Ryan Jacob
Chairperson
Director → Chairperson, 2023
On filings since 2021
18 hrs/week
No compensation reported
Ben O'Connor
Director
Director → Treasurer, 2021
Treasurer → Director, 2022
On filings since 2020
5 hrs/week
No compensation reported
Kelly David
Director
Director → Co-Vice Chairperson, 2021
Co-Vice Chairperson → Director, 2024
On filings since 2020
10 hrs/week
No compensation reported
Lauren Hoffer
Director
On filings since 2020
5 hrs/week
No compensation reported
Roy Azout
Director
On filings since 2020
5 hrs/week
No compensation reported
Nora Xu
Director
On filings since 2021
5 hrs/week
No compensation reported
John Schlueter
Director
On filings since 2023
15 hrs/week
No compensation reported
Karly Warner
Director
New on the 2024 filing
5 hrs/week
No compensation reported
Ryan K. Fischer
Chief Operating Oficer
On filings since 2023
40 hrs/week
$198K (2023) → $286K (2024)
Kena Pearson
Chief Financial Officer
New on the 2024 filing
40 hrs/week
$233K (2024)
Michele Golombuski
Chief Development Officer
New on the 2024 filing
40 hrs/week
$210K (2024)
Allyson Berent
Chief Science Officer
On filings since 2020
2 hrs/week
No compensation reported
Amelia Beatty
Secretary
Director → Secretary, 2022
On filings since 2020
15 hrs/week
No compensation reported
Michael Hanrahan
Vice Chairperson
Co-Vice Chairperson → Vice Chairperson, 2024
On filings since 2023
10 hrs/week
No compensation reported
Guy Shapiral
Tresurer
New on the 2024 filing
15 hrs/week
No compensation reported
Former officers (11)
- Former: Kena Richert (2020–2023) — Chief Financial Officer
- Former: Kristy Dixon (2020–2023) — Tresurer
- Former: Maiddy Dunigan (2020–2023) — Former Officer & COO
- Former: Megan Cross (2021–2023) — Chief Information Officer
- Former: John Schuellter (2020–2022) — Chairperson
- Former: Paula Evans (2020–2022) — Former Officer & Director
- Former: Sam Maydew (2020–2021) — Director
- Former: Bryan Thompson (2020) — Director
- Former: Chloe Knouff (2020) — Director
- Former: David Gurzick (2020) — Director
- Former: Debbie Guagliardo (2020) — Former Officer & Director
Data from IRS Form 990 filings, 2020–2024. "On filings since" is the earliest filing we hold that lists the person; hours are average hours per week as reported.
Compensation Overview
From 2024 IRS filing
The highest reported compensation on the 2024 filing was $286K, to Ryan K Fischer (Chief Operating Oficer). 4 officers or directors reported compensation on that filing.
Frequently asked questions about Foundation for Angelman Syndrome Therapeutics
How much does Foundation for Angelman Syndrome Therapeutics give each year?
Foundation for Angelman Syndrome Therapeutics gave $7.9M across 10 grants in 2024, according to its 2024 IRS Form 990. In 2023 it gave $5.6M across 17 grants.
What is Foundation for Angelman Syndrome Therapeutics's typical grant size?
Foundation for Angelman Syndrome Therapeutics's median grant in 2024 was $242,378, and its average grant was $792,128, across 10 grants on its 2024 IRS Form 990.
Where does Foundation for Angelman Syndrome Therapeutics give grants?
Foundation for Angelman Syndrome Therapeutics gives mostly in Pennsylvania: 74% of the grant dollars itemized on its 2024 IRS Form 990 went to recipients there. The next largest states were California (8%) and Massachusetts (6%). The most frequent recipient cities were Providence, RI (2 grants).
Does Foundation for Angelman Syndrome Therapeutics give general operating support?
Not in 2024: none of the 10 grants with a stated purpose on Foundation for Angelman Syndrome Therapeutics's 2024 IRS Form 990 were described as general or operating support.
Who are Foundation for Angelman Syndrome Therapeutics's largest grantees?
Foundation for Angelman Syndrome Therapeutics's largest 2024 grantees include University of Pennsylvania ($5,860,869), Boston Children's Hospital ($470,957) and Rush University Medical Center ($320,500), according to its 2024 IRS Form 990. Together they received 84% of its itemized 2024 grant dollars.
How large is Foundation for Angelman Syndrome Therapeutics?
Foundation for Angelman Syndrome Therapeutics reported $44.9M in total assets on its 2024 IRS Form 990. Its revenue that year was $5.4M.
What does Foundation for Angelman Syndrome Therapeutics fund?
In its filing, FAST describes itself as an organization of families and professionals dedicated to finding a cure for Angelman syndrome and related disorders through research funding, education, advocacy, and community support. See mission & focus areas ↑
How do I apply for a grant from Foundation for Angelman Syndrome Therapeutics?
FAST uses a rolling application process; applicants should submit a letter of intent for the relevant program before applying. Eligibility and process details are in the grantmaking section of this profile. See how to apply ↑
What is Foundation for Angelman Syndrome Therapeutics's EIN?
Foundation for Angelman Syndrome Therapeutics's EIN (Employer Identification Number) is 26-3160079. IRS Form 990 filing data is available on this page for 2020–2024.
Data last updated October 2026. Sourced from IRS Form 990 filings. Research dossier generated October 2026.
Data update history
(6)
When this profile's IRS filing data changed on Grantable
- Updated Form 990 for fiscal year 2020 (received by the IRS October 15, 2021)
- Updated Form 990 for fiscal year 2021 (received by the IRS November 15, 2022)
- Updated Form 990 for fiscal year 2022 (received by the IRS November 15, 2023)
- Updated Form 990 for fiscal year 2023 (received by the IRS November 15, 2024)
- Updated Form 990 for fiscal year 2024 (received by the IRS September 29, 2025)
- IRS filings on file for fiscal years 2020–2024
Live grants for the work Foundation for Angelman Syndrome Therapeutics funds
Medical Research Open opportunities, soonest deadline first.
- Dr. Richard A. Falls Virginia Lions Eye Institute Research Grant Up to $40,000 (yearly total budget) · Due October 25, 2026
- NSF Graduate Research Fellowship Program (GRFP) $32,000 annually plus $12,000 cost of education allowance · Due October 27, 2026
- Social, Political and Economic Inequality Grants Due October 28, 2026
Explore Open Grants
Browse active grant opportunities in Foundation for Angelman Syndrome Therapeutics's focus areas in our free grants database
Similar Funders
Funders that support many of the same organizations
Emergency Medicine Foundation
Irving, TX
The Emergency Medicine Foundation funds research and education to improve emergency medicine and patient care, including investigator-initiated, early-career, pilot, resident, and student research. In 2025, grants ranged from $3,500 to $986,839, with a median of $15,000; it funds U.S.-based institutions, with the largest shares of recent giving going to Texas and Pennsylvania. It invites applications through its listed grant opportunities; the profile does not state whether it accepts unsolicited requests outside those programs.
Assets
$10.6M
Grants
20
Total Given
$2.1M
National Alliance for Research on Schizophrenia and Depression
New York, NY
The Brain & Behavior Research Foundation funds scientific research into the causes, treatment, and prevention of serious mental illnesses, including schizophrenia, depression, anxiety, and bipolar disorder. Its 2024 grants had a median of about $70,000 and supported research institutions across multiple U.S. states; the Young Investigator program is explicitly U.S.-based. Applicants use award-specific application processes, but the profile does not state whether unsolicited requests are accepted.
Assets
$62.4M
Grants
80
Total Given
$8.4M
National Collegiate Inventors & Innovators Alliance Inc
Hadley, MA
VentureWell funds higher-education innovation and entrepreneurship, including early-stage science and engineering projects and faculty initiatives; some programs award grants to U.S. colleges and universities rather than directly to individuals or ventures. In 2025, its 69 grants ranged from $7,980 to $4 million, with a median of $25,000, and went to recipients across the United States. The profile describes application processes for specific programs but does not state whether unsolicited requests are accepted.
Assets
$89.5M
Grants
69
Total Given
$38.4M
The Broad Institute Inc
Cambridge, MA
The Broad Institute funds biomedical research, especially work on disease causes, treatments, cancer, and research technologies, primarily through grants to universities, hospitals, and research centers. In 2025, grants ranged from $8,419 to $15.75 million, with a median of about $301,000; most funding went to Massachusetts organizations. The profile does not state whether it accepts unsolicited requests.
Assets
$3.5B
Grants
77
Total Given
$86.0M
American Academy of Pediatrics
Itasca, IL
AAP funds child-health projects, including community-based care and access initiatives, pediatric chapter activities, and work on issues such as mental health, immunization, and disease prevention. Its 2025 grants ranged from $5,400 to $127,327, with a median of $15,970; U.S. and Canadian projects may apply to CATCH through its application process, while International CATCH supports eligible low- and lower-middle-income countries.
Assets
$177.8M
Grants
82
Total Given
$1.9M
Brightfocus Foundation
Clarksburg, MD
BrightFocus Foundation funds basic, translational, and clinical research on Alzheimer’s disease, macular degeneration, and glaucoma, including innovative and early-stage projects, worldwide. Its 2025 grants ranged from $15,240 to $409,500, with a median of $200,000. It accepts applications through online program opportunities and Requests for Proposals.
Assets
$65.1M
Grants
57
Total Given
$13.3M
More similar funders
More Funders in Texas
Cite this profile
Grantable. (2026). Foundation for Angelman Syndrome Therapeutics funder profile. GrantGraph. Retrieved October 25, 2026, from https://grantable.co/funders/foundation-for-angelman-syndrome-therapeutics-morg_8c216cff50fd4dc6aefc3c1825badf69
BibTeX
@misc{grantable_263160079_2026,
author = {{Grantable}},
title = {{Foundation for Angelman Syndrome Therapeutics funder profile}},
howpublished = {GrantGraph},
year = {2026},
url = {https://grantable.co/funders/foundation-for-angelman-syndrome-therapeutics-morg_8c216cff50fd4dc6aefc3c1825badf69},
note = {Accessed 2026-10-25. Data licensed CC BY 4.0}
}The figures on this page are open data under CC BY 4.0: reuse them with credit to Grantable and a link. Download the data.
Figures come from Foundation for Angelman Syndrome Therapeutics's IRS filings (methodology). AI-written summaries, news items and logos are not covered by the open licence. Spot an error? Email hello@grantable.co.
Foundation for Angelman Syndrome Therapeutics down — hundreds of funders to go?